These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 25182153)

  • 1. L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer.
    Shim EH; Livi CB; Rakheja D; Tan J; Benson D; Parekh V; Kho EY; Ghosh AP; Kirkman R; Velu S; Dutta S; Chenna B; Rea SL; Mishur RJ; Li Q; Johnson-Pais TL; Guo L; Bae S; Wei S; Block K; Sudarshan S
    Cancer Discov; 2014 Nov; 4(11):1290-8. PubMed ID: 25182153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teleological role of L-2-hydroxyglutarate dehydrogenase in the kidney.
    Brinkley G; Nam H; Shim E; Kirkman R; Kundu A; Karki S; Heidarian Y; Tennessen JM; Liu J; Locasale JW; Guo T; Wei S; Gordetsky J; Johnson-Pais TL; Absher D; Rakheja D; Challa AK; Sudarshan S
    Dis Model Mech; 2020 Nov; 13(11):. PubMed ID: 32928875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal oncometabolite L-2-hydroxyglutarate imposes a block in kidney tubulogenesis: Evidence for an epigenetic basis for the L-2HG-induced impairment of differentiation.
    Taub M; Mahmoudzadeh NH; Tennessen JM; Sudarshan S
    Front Endocrinol (Lausanne); 2022; 13():932286. PubMed ID: 36133305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncometabolite L-2-hydroxyglurate directly induces vasculogenic mimicry through PHLDB2 in renal cell carcinoma.
    Wang H; Wang L; Zheng Q; Lu Z; Chen Y; Shen D; Xue D; Jiang M; Ding L; Zhang J; Wu H; Xia L; Qian J; Li G; Lu J
    Int J Cancer; 2021 Apr; 148(7):1743-1755. PubMed ID: 33320958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Another small molecule in the oncometabolite mix: L-2-Hydroxyglutarate in kidney cancer.
    Shim EH; Sudarshan S
    Oncoscience; 2015; 2(5):483-6. PubMed ID: 26097881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of the oncometabolite enantiomers of 2-hydroxyglutarate and their metabolism by diverse dehydrogenases.
    Garcia I; Cornely K; Peterson CN; Berkmen MB
    Essays Biochem; 2024 Oct; 68(2):161-171. PubMed ID: 38919140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer.
    Shelar S; Shim EH; Brinkley GJ; Kundu A; Carobbio F; Poston T; Tan J; Parekh V; Benson D; Crossman DK; Buckhaults PJ; Rakheja D; Kirkman R; Sato Y; Ogawa S; Dutta S; Velu SE; Emberley E; Pan A; Chen J; Huang T; Absher D; Becker A; Kunick C; Sudarshan S
    Clin Cancer Res; 2018 Dec; 24(24):6433-6446. PubMed ID: 30108105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative Analysis of Oncometabolite 2-Hydroxyglutarate.
    Yuan BF
    Adv Exp Med Biol; 2021; 1280():161-172. PubMed ID: 33791981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia Induces Production of L-2-Hydroxyglutarate.
    Intlekofer AM; Dematteo RG; Venneti S; Finley LW; Lu C; Judkins AR; Rustenburg AS; Grinaway PB; Chodera JD; Cross JR; Thompson CB
    Cell Metab; 2015 Aug; 22(2):304-11. PubMed ID: 26212717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. l-2-Hydroxyglutarate remodeling of the epigenome and epitranscriptome creates a metabolic vulnerability in kidney cancer models.
    Kundu A; Brinkley GJ; Nam H; Karki S; Kirkman R; Pandit M; Shim E; Widden H; Liu J; Heidarian Y; Mahmoudzadeh NH; Fitt AJ; Absher D; Ding HF; Crossman DK; Placzek WJ; Locasale JW; Rakheja D; McConathy JE; Ramachandran R; Bae S; Tennessen JM; Sudarshan S
    J Clin Invest; 2024 May; 134(13):. PubMed ID: 38743486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma.
    Miyake K; Baba Y; Ishimoto T; Hiyoshi Y; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Ogata Y; Nagayama M; Silsirivanit A; Kobayashi D; Araki N; Baba H
    Med Oncol; 2018 Nov; 36(1):11. PubMed ID: 30506321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells.
    Smolková K; Dvořák A; Zelenka J; Vítek L; Ježek P
    Int J Biochem Cell Biol; 2015 Aug; 65():125-33. PubMed ID: 26007236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncometabolite d-2HG alters T cell metabolism to impair CD8
    Notarangelo G; Spinelli JB; Perez EM; Baker GJ; Kurmi K; Elia I; Stopka SA; Baquer G; Lin JR; Golby AJ; Joshi S; Baron HF; Drijvers JM; Georgiev P; Ringel AE; Zaganjor E; McBrayer SK; Sorger PK; Sharpe AH; Wucherpfennig KW; Santagata S; Agar NYR; Suvà ML; Haigis MC
    Science; 2022 Sep; 377(6614):1519-1529. PubMed ID: 36173860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drosophila larvae synthesize the putative oncometabolite L-2-hydroxyglutarate during normal developmental growth.
    Li H; Chawla G; Hurlburt AJ; Sterrett MC; Zaslaver O; Cox J; Karty JA; Rosebrock AP; Caudy AA; Tennessen JM
    Proc Natl Acad Sci U S A; 2017 Feb; 114(6):1353-1358. PubMed ID: 28115720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor.
    Elhammali A; Ippolito JE; Collins L; Crowley J; Marasa J; Piwnica-Worms D
    Cancer Discov; 2014 Jul; 4(7):828-39. PubMed ID: 24740997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Hydroxyglutarate in Cancer Cells.
    Ježek P
    Antioxid Redox Signal; 2020 Nov; 33(13):903-926. PubMed ID: 31847543
    [No Abstract]   [Full Text] [Related]  

  • 17. Renal L-2-hydroxyglutarate dehydrogenase activity promotes hypoxia tolerance and mitochondrial metabolism in Drosophila melanogaster.
    Mahmoudzadeh NH; Heidarian Y; Tourigny JP; Fitt AJ; Beebe K; Li H; Luhur A; Buddika K; Mungcal L; Kundu A; Policastro RA; Brinkley GJ; Zentner GE; Nemkov T; Pepin R; Chawla G; Sudarshan S; Rodan AR; D'Alessandro A; Tennessen JM
    Mol Metab; 2024 Nov; 89():102013. PubMed ID: 39182840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncometabolite D-2-Hydroxyglurate Directly Induces Epithelial-Mesenchymal Transition and is Associated with Distant Metastasis in Colorectal Cancer.
    Colvin H; Nishida N; Konno M; Haraguchi N; Takahashi H; Nishimura J; Hata T; Kawamoto K; Asai A; Tsunekuni K; Koseki J; Mizushima T; Satoh T; Doki Y; Mori M; Ishii H
    Sci Rep; 2016 Nov; 6():36289. PubMed ID: 27824159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
    Delahousse J; Verlingue L; Broutin S; Legoupil C; Touat M; Doucet L; Ammari S; Lacroix L; Ducreux M; Scoazec JY; Malka D; Paci A; Hollebecque A
    Eur J Cancer; 2018 Feb; 90():83-91. PubMed ID: 29274619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitive Determination of Onco-metabolites of D- and L-2-hydroxyglutarate Enantiomers by Chiral Derivatization Combined with Liquid Chromatography/Mass Spectrometry Analysis.
    Cheng QY; Xiong J; Huang W; Ma Q; Ci W; Feng YQ; Yuan BF
    Sci Rep; 2015 Oct; 5():15217. PubMed ID: 26458332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.